Limoges

• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 5 2019-06-05 Middle or low locally advanced resectable rectal carcinoma
• Randomised trial evaluating mifamurtide in combination with standard chemotherapy in patients with high-grade osteosarcoma at high risk of r … Recruiting
  2024-514780-26-00 4 2018-10-23 Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
• Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma … Recruiting
  2024-512827-36-00 4 2016-10-17 Penis carcinoma
• GRAALL2014 Recruiting
  2024-516103-16-00 4 2015-12-04 Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 5 2014-10-01 Children, adolescents and adults with newly diagnosed diffuse intrinsi
• PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended recruitment
  2025-521302-17-00 10 2026-05-26 Hihg risk of cholangiocarcinoma intra hépatic resectable
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended recruitment
  2024-516473-72-00 5 2025-07-31 Multifocal Motor Neuropathy
• A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Ended recruitment
  2024-515919-22-00 5 2025-06-02 Chronic Hepatitis D Virus (HDV) Infection
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• BOTAF - Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in pa … Ended recruitment
  2024-513645-37-00 5 2024-09-05 Adult patients with indication for conventional cardiac surgery (CABG,
• STUDY AGORA-1 / ALFA 2100: Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukem … Ended recruitment
  2023-504176-25-00 9 2024-08-08 Acute Myeloid Leukemia
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone … Ended recruitment
  2023-508310-41-00 4 2024-06-26 Multiple myeloma
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatme … Ended recruitment
  2022-501372-25-00 4 2024-01-10 Patients aged 18 years and older with relapsed or refractory FLT3 muta
• Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended recruitment
  2022-502010-85-00 9 2023-12-20 Non-Squamous Non-Small Cell Lung Cancer
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran … Ended recruitment
  2024-514876-41-00 9 2023-12-06 Higher-risk myelodysplastic syndromes untreated and ineligible for all
• A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He … Ended recruitment
  2023-503422-39-00 5 2023-10-20 Hepatocellular Carcinoma (HCC)
• Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended recruitment
  2024-514878-53-00 4 2023-10-04 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk intermediate-2 or

Showing 145–168 of 249 trials